These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12836223)

  • 1. [Quality control of gene therapy products: approach of the French Agency for the Safety of Health Products].
    Chenivesse X; Ridoux V; Tissier MH
    Med Sci (Paris); 2003 Apr; 19(4):481-8. PubMed ID: 12836223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Science of evaluating the characteristics, quality and safety of biotechnological products: RDNA-derived products, cell culture technology-derived products, gene therapy products, cellular therapy products, and transgenic animal-derived protein products and cellular products].
    Hayakawa T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):1-38. PubMed ID: 10859934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Union guidance on the quality, safety and efficacy of DNA vaccines and regulatory requirements.
    Robertson JS; Cichutek K
    Dev Biol (Basel); 2000; 104():53-6. PubMed ID: 11713824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust.
    Bamford KB; Wood S; Shaw RJ
    QJM; 2005 Feb; 98(2):75-86. PubMed ID: 15655100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirements for baculoviruses for clinical gene therapy applications.
    Lesch HP; Makkonen KE; Laitinen A; Määttä AM; Närvänen O; Airenne KJ; Ylä-Herttuala S
    J Invertebr Pathol; 2011 Jul; 107 Suppl():S106-12. PubMed ID: 21784225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic gene therapy. Present situation and future perspective.
    Gottschalk U; Chan S
    Arzneimittelforschung; 1998 Nov; 48(11):1111-20. PubMed ID: 9850435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Release testing of retroviral vectors and gene-modified cells.
    Nordling D; Kaiser A; Reeves L
    Methods Mol Biol; 2009; 506():265-79. PubMed ID: 19110632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Quality control of clinical-grade recombinant adenovirus used in gene therapy].
    Zhang XZ; Lin H; Yang XY; Wang CH; Zhang MM; Chen PL; Peng ZH
    Zhonghua Yi Xue Za Zhi; 2004 May; 84(10):849-52. PubMed ID: 15200892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Sanitary safety of GMOs used in therapeutics].
    Trouvin JH
    Bull Acad Natl Med; 2002; 186(8):1401-9. PubMed ID: 12669359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Public health safety and transfusion organization].
    Vachey L
    Bull Acad Natl Med; 1997 May; 181(5):853-61. PubMed ID: 9312360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cosmetovigilance: a French pharmacovigilance system for cosmetics developed by the French health products safety agency. A proposal for the future].
    Tissier MH; Lepagnol F
    Therapie; 2002; 57(3):273-82. PubMed ID: 12422542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy bio-safety: scientific and regulatory issues.
    Gonin P; Buchholz CJ; Pallardy M; Mezzina M
    Gene Ther; 2005 Oct; 12 Suppl 1():S146-52. PubMed ID: 16231047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vectors and delivery systems in gene therapy.
    Gardlík R; Pálffy R; Hodosy J; Lukács J; Turna J; Celec P
    Med Sci Monit; 2005 Apr; 11(4):RA110-21. PubMed ID: 15795707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three Rs potential in the development and quality control of immunobiologicals.
    Halder M
    ALTEX; 2001; 18 Suppl 1():13-47. PubMed ID: 11854853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Gene transfer systems and gene therapy].
    Yilmaz E
    Mikrobiyol Bul; 2003 Jan; 37(1):89-98. PubMed ID: 12838683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.